Progression of Atherosclerosis Is Associated With Variation in the α 1 -Antitrypsin Gene
- 1 April 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (4), 644-649
- https://doi.org/10.1161/01.atv.0000065196.61663.8d
Abstract
Objective— α 1 -Antitrypsin (AAT) protects elastic tissue and may play a role in atherogenesis. The association of atherosclerosis progression with common AAT variants was considered in 2 clinical trials. Methods and Results— We examined the association of AAT V213A, S and Z deficiency alleles, and the functional 3′ UTR 11478G>A with change in minimal luminal diameter, a measure of focal disease, in the Lopid Coronary Angiography Trial gemfibrozil study of post-bypass men. S or Z carriers (n=14) showed strong progression of disease on placebo (11.5%) but responded well to treatment (3% regression). 11478A carriers treated with placebo or gemfibrozil showed significantly more disease progression (n=8, −14.5% and n=16, −4.0%, respectively) than 11478GG men (n=107, −7.0% and n=108, −1.4%, respectively; overall, P =0.003). VV213 men treated with gemfibrozil (n=68) showed −4.8% progression, whereas A213 carriers (n=55) showed +1.4% regression of disease ( P =0.001). No V213A effect was seen on placebo ( P =0.11). In the Diabetes Atherosclerosis Intervention Study fenofibrate trial of angiographic progression in type 2 diabetes, the association of 11478A with increased disease progression was confirmed in the treatment group, but not the gemfibrozil-treated A213 association with regression, suggesting a pharmacogenetic difference. Conclusions— Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis.Keywords
This publication has 22 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor α Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery DiseaseCirculation, 2002
- Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS)The American Journal of Cardiology, 1999
- Elastin–elastase–atherosclerosis revisitedAtherosclerosis, 1998
- Mutation in an α1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factorsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997
- A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery: The rationale, design, and baseline characteristics of the LOCAT studyControlled Clinical Trials, 1997
- ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGINGAnnual Review of Medicine, 1995
- Point mutation in a 3′ flanking sequence of the alpha-1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequenceHuman Molecular Genetics, 1993
- The mechanism of Z α1-antitrypsin accumulation in the liverNature, 1992
- Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy.JCI Insight, 1990
- A computational procedure for determining energetically favorable binding sites on biologically important macromoleculesJournal of Medicinal Chemistry, 1985